Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.
